

In addition the patients were asked whether the eye-drops were an acceptable form of treatment.

For the 23 patients who completed the trial, the results were as follows:

5

Rating	No of patients	
	Patients' assessment	Clinicians' assessment
3	10	7
2	9	9
1	2	4
0	1	1

(One patient failed to record an opinion, and the clinician failed to record an opinion for two patients).

18 of the 23 patients recorded that they found the treatment acceptable.

We claim:

1. A method of treating a reversible obstructive airways disease comprising administering, by inhalation, to a patient suffering from, or susceptible to, such a condition the nebulized contents of an ampoule of carbon dioxide permeable plastics material filled with a unit dose of an aqueous pharmaceutical solution containing, as active ingredient, from 0.1 to 5% w/v of 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyran(3,2-g)quinoline-2,8-dicarboxylic acid or a pharmaceutically acceptable salt thereof, the solution having a pH of 3.5 to 6.0.

2. The method of treatment according to claim 1, wherein the concentration of the active ingredient in the solution is from 0.1 to 1.0% w/v.

3. The method of treatment according to claim 1, wherein the active ingredient is nedocromil sodium.

35

40

45

50

55

60

65

08916578-08297

We claim:

1 4. A method of treatment of a disease selected from the group consisting of
2 conjunctivitis, keratitis, allergic eyes, and anterior uveitis, which method comprises
3 administering to the eye an effective amount of an ophthalmically acceptable aqueous
4 pharmaceutical solution containing an active ingredient 9-ethyl-6, -dihydro-4, 6-dioxo-10-
5 propyl-4H-pyrano(3,2g)quinoline-2, 8-dicarboxylic acid, or a pharmaceutically acceptable salt
6 thereof.

1 5. The method of claim 4, wherein the disease is conjunctivitis.

1 6. The method of claim 5, wherein the disease is seasonal allergic conjunctivitis.

1 7. The method of claim 5, wherein the disease is allergic conjunctivitis.

1 8. The method of claim 5, wherein the disease is vernal conjunctivitis.

1 9 The method of claims 4, 5, 6, 7 or 8, wherein said active ingredient is nedocromil
2 sodium.

1 10. A method of controlling the symptoms of conjunctivitis comprising administering
2 to the eye of a patient having conjunctivitis an effective amount of nedocromil sodium in an
3 ophthalmically acceptable formulation.

1 11. The method of claim 10, wherein the conjunctivitis is vernal conjunctivitis.

1 12. The method of claim 10, wherein the conjunctivitis is allergic conjunctivitis.

1 13. The method of claim 10, wherein the conjunctivitis is seasonal allergic
2 conjunctivitis.

add
C17